Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3630200 A
Publication typeGrant
Publication dateDec 28, 1971
Filing dateJun 9, 1969
Priority dateJun 9, 1969
Publication numberUS 3630200 A, US 3630200A, US-A-3630200, US3630200 A, US3630200A
InventorsHiguchi Takeru
Original AssigneeAlza Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Ocular insert
US 3630200 A
Abstract  available in
Images(1)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent [72] Inventor Takeru Higuchi Lawrence, Kans. [21] Appl. No. 831,481 [22] Filed June 9, 1969 [45] Patented Dec. 28, 1971 [73] Assignee ALZA Corporation [54] OCULAR INSERT 22 Claims, 2 Drawing Figs.

[52] U.S. C1 [51] lnt.Cl.. ..A61m 31/00 [50] Field 01 Search 128/260,

[56] References Cited UNITED STATES PATENTS 3,006,338 10/1961 Davies 128/156 Primary Examiner-Robert W. Michell Assistant Examiner-R. P. Dyer A!!orneySteven D. Goldby ABSTRACT: Drug dispensing ocular insert for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lid to dispense drug to the eye over a prolonged period of time is rendered more compatible with the eye and surrounding tissues by fabricating the insert of an inner core containing the drug and a soft hydrophilic outer layer.

' PATENTEDnmsmn I 31530200 Fig.2

INVENTOR.

Takeru Hiquc MAQW Attorney OCULAR INSERT BACKGROUND OF THE INVENTION This invention relates to an ocular insert for dispensing drugs to the eye and, more especially, to an ocular insert having improved compatibility with the eye and surrounding tissues.

At the present time, diseases of the eye are treated by applying ophthalmic drugs in liquid or ointment form. To be effective in many cases, the application of drug should be substantially continuous. Such continuous delivery of drug is not obtained through the use of liquid or ointment dosage forms, even though they be applied at intervals during the day and night. Periodic application of these dosage forms results in the eye receiving a massive, but unpredictable, amount of drug at the time of application but the drug is washed away rapidly by tears, leaving the eye without medication until the next application. Ointment dosage forms are presently available only in unsterilized form and this too presents a problem. 1

At a very early time, drugs were dissolved or dispersed in a water soluble gel of glycerinated gelatin that was shaped to the form of a lamella or eye disk. These lamellae were applied to the inner surface of the eyelid to supply drug to the eye. In use, the glycerinated gelatin vehicle dissolved rapidly in tear liquid, producing the same type of effect as liquid dosage forms. Lamellae were not a sustained release dosage form. To my knowledge, they are not used in this country, although they may be used to a small extent in Europe. Further information on these water soluble dosage forms can be found in Remingtons Pharmaceutical Sciences, XIII, pages 547-8 (Mack Publishing Co., Easton, Pa. 1965); Fishburn, An Introduction to Pharmaceutical Formulation, page 1 l6 (Pergamon Press Ltd., New York City, N.Y. 1965); and U5. Pat. No. 273,410, Mar. 6, 1883.

US. Pat. No. 3,416,530, granted Dec. 17, 1968, and assigned to the assignee of this invention, is directed to the invention of a drug dispensing ocular insert that truly acts as a depot or drug reservoir, retaining and slowly releasing drug to the eye for prolonged periods of time. Such ocular inserts are fabricated of flexible polymeric materials that are biologically inert, nonallergenic, and insoluble in tear liquid. To initiate the therapeutic program, the ocular insert is placed in the culde-sac of the conjunctiva between the sclera of the eyeball and the lid. Since the polymeric material from which the ocular insert is formed is insoluble in tear liquid it retains its integrity and remains intact during the course of therapy, acting as a reservoir to continuously release drug to the eye and surrounding tissues at a rate which is not affected by dissolution or erosion of the polymeric material. On termination of the therapeutic program, the ocular insert is removed from the cul-de-sac. Thus, a single such ocular insert provides the complete ophthalmic dosage regime for a particular time period, on the order of 24 hours or longer. Frequent repeated applications, as is necessary with liquids, ointments, or water soluble lamellae, often requiring awakening the patient during the night, are avoided.

The necessary characteristics for the material used to fabricate the ocular insert and obtain the desired drug metering effect are dependent on the particular drug used. With many drugs, hydrophobic polymeric materials having a relatively high affinity for the drug should be used in forming the ocular insert. Otherwise, the drug will be rapidly released from the ocular insert and the objective of continuous and sustained release defeated. However, many hydrophobic polymers having the desired drug retention and release characteristics tend to be irritating to the eye and surrounding tissues. To provide compatibility with the eye and surrounding tissues, it has been found that the surface of the ocular insert in contact with the eye and surrounding tissues should be soft and hydrophilic. Since hydrophilic materials do not have the drug retention characteristics needed for many drugs, it has been necessary at times in the past to select materials which compromise the desired comfort and tissue compatibility with the desired retention and release characteristics for the drug.

SUMMARY OF THE INVENTION Accordingly, it is an object of this invention to provide an improved ocular insert that is compatible with and nonirritating to the eye and surrounding tissues.

Another object of this invention is to provide an improved ocular insert which can retain and slowly release a wide variety of drugs to the eye.

In attaining the objects of this invention, one feature resides in a drug dispensing ocular insert comprising a flexible body containing a drug and adapted for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lid to dispense drug to the eye over a prolonged period of time. The ocular insert is rendered more compatible with the eye and surrounding tissues by comprising it of an inner core containing the drug and having an affinity therefor and a soft, hydrophilic outer layer.

Another feature of this invention resides in the ocular insert described above wherein the inner core is a hydrophobic polymer having an affinity for drugs and capable of slowly releasing such drugs to the eye over a prolonged period of time.

Other objects, features, and advantages of this invention will become more apparent from the following description when taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS In the drawings FIG. I is a cross-sectional view of the ocular insert of this invention and FIG. 2 is a cross-sectional view of a modified ocular insert of this invention.

As illustrated in FIG. 1, the ocular insert 10 of this invention is comprised of an inner core II, which is a matrix having drug 12 dispersed therethrough. Surrounding inner core 11 is an outer layer I3 of a soft hydrophilic material. Drug l2 gradually difi'uses through or is leached from inner core II and passes through hydrophilic outer layer 13 to the eye and surrounding tissues.

In FIG. 2, the modified ocular insert 10 of the invention has a hollow inner core 11 having an interior chamber I4 containing drug I2. As with the other form of the ocular insert, drug 12 gradually diffuses through or is leached by tear liquid from the walls of inner core 11, passes through outer layer I3 and contacts the eye and surrounding tissues.

DETAILED DESCRIPTION OF THE INVENTION To use the ocular insert of the invention, it is inserted in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lid. While the ocular insert can be inserted under either the upper lid or the lower lid, placement of the ocular insert under the lower lid is preferred. The eye has a tendency to roll upwardly during sleeping, known as Bells Phenomenon, which may cause discomfort to some persons if the ocular insert is under the upper lid. Once in place, the ocular insert functions as a drug reservoir gradually releasing drug to the eye and surrounding tissues. Drug leaving the ocular insert, whether by diffusion through the walls of the insert or as a result of the leaching action of tear liquid, is transported to the eyeball by the flow of tear liquid or by the blinking action of the eyelids.

By use of the ocular insert, the eye is continuously bathed with drug over a particular time span. Normally, the ocular insert will be retained in place for a period of 24 hours, thereby supplying the complete dosage regime for eye therapy over that period of time. Because the outer layer of the ocular insert is formed of a soft hydrophilic material, the device can remain in place for long periods of time without causing discomfort to the patient. This is achieved without sacrificing the necessary drug retention and release properties, since the inner core, which does not contact the eye and surrounding tissues, can be selected based on these properties.

The ocular insert can be fabricated in any convenient shape for comfortable retention in the cul-de-sac. Thus, the marginal outline of the ocular insert can be ellipsoid, beanshape, rectangular, etc. In cross section, it can be concavoconvex, rectangular, etc. As the ocular insert is flexible and, in use, will assume essentially the configuration of the cul-de-sac, the original shape of the device is not of controlling importance. Dimensions of the device can vary widely. The lower limit on the size of the device is governed by the amount of the particular drug to be supplied to the eye and surrounding tissues to elicit the desired pharmacologic response, as well as by the smallest sized device which conveniently can be inserted and removed from the eye. The upper limit on the size of the device is governed by the limited space within the cul-de-sac that conveniently and comfortably can be filled with an ocular insert. Typically, the ocular insert is 4 to millimeters in length, 1 to 12 millimeters in width, and 0.1 to 1 millimeter in thickness.

Any of the drugs used to treat the eye and surrounding tissues can be incorporated in the ocular insert of this invention. Also, it is practical to use the eye and surrounding tissues as a point of entry for systemic drugs that enter circulation in the blood stream and produce a pharmacologic response at a site remote from the point of application of the ocular insert. Thus, drugs which will pass through the eye or the tissue surrounding the eye to the blood stream, but which are not used in therapy of the eye itself, can be incorporated in the ocular insert.

Suitable drugs for use in therapy of the eye with the ocular insert of this invention include, without limitation: Anti-infectives: such as antibiotics, including tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole and sulfisoxazole; antivirals, including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate; Antiallergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine; Antiinflammatories such as hydrocortisone, hydrocortisone acetate, dexamethasone, dexamethasone 21-phosphate, fluocinolone, medrysone, prednisolone, prednisolone 21- phosphate, and prednisolone acetate; Decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, diisopropyl fluorophosphate, phospholine iodide, and demecarium bromide; Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine; and Sympathomimetics such as epinefrine. Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or nonirritating, pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g. quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc., which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc. can be employed. The amount of drug incorporated in the ocular insert varies widely depending on the particular drug, the desired therapeutic effect, and the time span for which the ocular insert will be used. Since the ocular insert is intended to provide the complete dosage regime for eye therapy for but a particular time span, such as 24 hours, there is no critical upper limit on the amount of drug incorporated in the device. For when the device is removed and disposed of it makes little difference whether any drug remains in the device. The lower limit will depend on the activity of the drug and its capability of being released from the device. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the device. However, typically, from 1 microgram to l milligram of drug is incorporated in the ocular insert.

As described and illustrated above, the inner core of the ocular insert can be a matrix with the drug dispersed therethrough or can be a hollow capsule with the drug within its interior chamber. The inner core need not be a unitary member but can be made up of discrete particles or hollow capsules which release drug by diffusion or the leaching action of tear liquid. Since the function of the inner core is to act as the reservoir for the drug, it is fabricated, in each case, of a material that provides the optimal environment for the desired depot and release characteristics for the drug being used. No compromise between the retention and release characteristics and the compatibility with the eye and surrounding tissues must be made when designing the device of this invention since the outer layer is independently selected for its eye and tissue compatibility. Suitable materials for the inner core are those flexible materials through which the drug will diffuse or be leached by the action of tear liquid at a slow rate. Exemplary materials for fabricating the inner core of the device include hydrophobic polymers such as polyvinylchloride either unplasticized or plasticized with long chain .fatty amides or other plasticizer, plasticized nylon, unplasticized soft nylon, silicone rubber, and polyethylene; and hydrophilic polymers such as the hydrophilic hydrogels of esters of acrylic and methacrylic acid (as described in U.S. Pats. Nos. 2,976,576 and 3,220,960 and Belgian Pat. No. 701,813), modified collagen, cross-linked hydrophilic polyether gels (as described in U.S. Pat. No. 3,419,006), cross-linked polyvinylalcohol, cross-linked partially hydrolyzed polyvinylacetate, cellulosic gels such as methylcellulose and hydroxyethylcellulose; and ion exchange resins, especially those with a low degree of cross-linkings. By using hydrophobic polymers as the core material, one obtains the maximum advantages from the present invention since this invention overcomes the disadvantages inherent in use of hydrophobic polymers in previously known ocular inserts.

Specific, but nonlimiting, examples of combinations of drugs and polymers for the inner core are:

1. chloramphenicol incorporated into polyethylene terephthalate plasticized with higher alcohols;

2. promethazine trichloroacetate incorporated into polyvinyl chloride plasticized with dioctylphthalate;

3. chloramphenicol dispersed throughout polydimethylsiloxane;

4. pilocarpine or pilocarpine perfluorobutyrate incorporated into polyvinyl chloride plasticized with dioctylseboate; and

5. dexamethasone incorporated into 6-6 nylon plasticized with higher alcohols.

In the ocular insert of this invention, the outer layer functions to render the device compatible with the eye and surrounding tissues and comfortable to the wearer. It should not provide a significant barrier to flow or passage of drug from the inner core to the eye and surrounding tissues. Materials used in fabricating the outer layer of the ocular insert are soft, flexible, hydrophilic, and insoluble in tear liquid. While these materials are hydrophilic and absorb water, they should not be substantially eroded or dissolved in the tear liquid. Exemplary materials include hydrophilic hydrogels of esters of acrylic and methacrylic acid (as described in U.S. Pats. Nos. 2,976,576 and 3,220,960, and Belgian Pat. No. 701,813), modified collagen, cross-linked hydrophilic polyether gels (as described in U.S. Pat. No. 3,419,006), cross-linked polyvinylalcohol, cross-linked partially hydrolyzed polyvinylacetate, and cellulosic gels such as methylcellulose and hydroxyethyl cellulose. Of course, the hydrophilic material used to form the outer layer will, in each case, have different characteristics than the material used to form the inner core of the particular ocular insert. Such hydrophilic materials are permeable to gases and liquids which is desirable in the eye since it permits free transfer of eye fluids, drugs, and oxygen. In a preferred embodiment of this invention, the inner core is also porous to liquid and gas flow to assist in the transfer of oxygen and eye fluids through the ocular insert.

The relative thickness of the inner core and the outer hydrophilic layer can vary widely and is not a limitation on the invention.

Drug can be incorporated in the inner core in many ways. When the inner core is a hollow capsule, any of the encapsulation techniques conventionally used can be employed. When the inner core is a solid matrix with the drug dispersed therethrough, the inner core can be fabricated by adding the drug to the monomers prior to polymerization; adding the drug to the polymer in liquid form, molding, and curing; or by impregnating the inner core with the drug. Thereafter, the inner core, containing the drug, can be coated with or laminated to the hydrophilic outer layer. When lamination is employed to fabricate the insert, the device may comprise a sheet of inner core material sandwiched between two sheets of outer layer material. To enhance adhesion between the layers, the inner core can be perforated or embossed.

In a specific example of the manufacture of a device of the invention, liquid polydimethylsiloxane (Dow Corning Silastic) is mixed with chloramphenicol antibiotic. After uniformly mixing the antibiotic with the unvulcanized layers, the inner core can be perforated or embossed.

In a specific example of the manufacture of a device of the invention, liquid polydimethylsiloxane (Dow Corning Silastic) is mixed with chloramphenicol antibiotic. After uniformly mixing the antibiotic with the unvulcanized silicone rubber, stannous octoate catalyst (0.5 percent by weight) is added and the mixture is poured into a mold having a cavity 8X2X0.2 mm. to cure the silicone rubber at room temperature. The resulting silicone rubber body contains 0.5 milligram of chloramphenicol. 2-hydroxyethyl methacrylate 100 parts by weight) is mixed with tertiary butyl peroctoate (0.2 part by weight) and ethylene glycol dimethacrylate (0.2 by weight) to provide a casting syrup which is coated onto the foregoing silicone rubber body in a mold and cured at 70 C. The dimensions of the resulting ocular insert are l0 4X0.8 mm. lmmediately prior to use, the outer surface of the ocular insert is wet with water which softens the hydrophilic poly (hydroxyethyl methacrylate) outer layer forming a hydrogel thereof. When inserted in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lid, the ocular insert is effective to deliver to the eye the dose of chloramphenicol antibiotic required for 24 hours of treatment of infection. The soft hydrophilic outer layer is compatible with the eye and surrounding tissues and produces no irritation or discomfort.

Thus, the improved ocular insert of this invention offers many advantages. The inner core material, which functions as the drug reservoir to retain and release the drug, can be chosen so as to produce the optimum environment for the drug. In selecting this material, one need not consider its compatibility with the eye and surrounding tissues since the ocular insert includes an external layer that is soft, flexible, hydrophilic, and compatible with the eye and surrounding tissues.

While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, those skilled in the art will appreciate that various modifications, changes, and omissions in the ocular insert illustrated and described can be made without departing from the spirit of the invention. It is the intention, therefore, to be limited only by the scope of the following claims.

What is claimed is:

l. In a drug dispensing ocular insert comprising a flexible body containing a drug and adapted for insertion into the culde-sac of the conjunctiva between the sclera of the eyeball and the lid to dispense said drug to the eye over a prolonged period of time, the improvement for rendering the ocular insert more compatible with the eye and the surrounding tissues comprising (1) an inner core comprised of a hydrophobic polymer, said inner core containing the drug and permeable to passage of the drug and (2) a soft flexible 2. The ocular insert of claim 1 wherein said inner core is porous to permit passage of gases and liquids therethrough.

3. The ocular insert of claim 1 wherein said inner core is a matrix ofa hydrophobic polymer permeable to passage of the drug, to meter the passage of drug from the inner core to and through the hydrophilic outer layer.

4. The ocular insert of claim 3 wherein said hydrophilic outer layer is a hydrophilic hydrogel.

5. The ocular insert of claim 3 wherein said hydrophilic outer layer is a hydrophilic hydrogel of a polymer of an ester of acrylic acid or methacrylic acid.

6. The ocular insert of claim 1 wherein said inner core is comprised of a plurality of drug-containing particles.

7. The ocular insert of claim 1 wherein said inner core is a capsule of a hydrophobic polymer, having the drug in the interior chamber thereof, the walls of said capsule being permeable to passage of the drug, to meter the flow of drug from said interior chamber to and through the hydrophilic outer layer.

8. The ocular insert of claim 7 wherein said hydrophilic outer layer is a hydrophilic hydrogel. I

9. The ocular insert of claim 7 wherein said hydrophilic outer layer is a hydrophilic hydrogel of a polymer of an ester of acrylic or methacrylic acid.

10. The ocular insert of claim 1 wherein said hydrophilic outer layer is comprised of a polymer selected from the group consisting of hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross linked hydrophilic polyether gel, cross linked polyvinyl alcohol, cross-linked partially hydrolyzed polyvinyl acetate and cellulosic gel.

11. The ocular insert of claim 1 wherein said drug is an ophthalmic drug.

12. The ocular insert of claim 1 wherein said drug is a systematically active drug which will pass through the eye to the bloodstream and produce a pharmacologic response at a site remote from the eye.

13. The ocular insert of claim 1 wherein said drug is a systemically active drug which will pass through the tissue surrounding the eye to the bloodstream and produce a pharmacologic response at a site remote from the eye.

14. The ocular insert of claim 1 wherein from I microgram to l milligram of drug is incorporated in said tablet.

15. The ocular insert of claim 1 wherein same ranges from 4 to 20 millimeters in length, l to 12 millimeters in width, and 0.1 to l millimeter in thickness.

16. In a drug dispensing ocular insert comprising a flexible body containing a drug and adapted for insertion into the cul de-sac of the conjunctiva between the sclera of the eyeball and the lid to dispense said drug to the eye over a prolonged period of time, the improvement for rendering the ocular insert more compatible with the eye and the surrounding tissues comprising 1) an inner core containing the drug and having an affinity therefor, and said inner core being comprised of material permeable to passage of the drug, which material is independently selected to provide the desired drug release rate, and (l a soft flexible hydrophilic outer layer insoluble in tear liquid, said outer layer also being permeable to passage of the drug and being independently selected for its eye and tissue compatibility, but providing no significant barrier to flow or passage of the drug from the said inner core l to the eye and surrounding tissue, whereby there is no compromise in selection of material for the inner core (1) having the desired release rate for the drug therein by reason of the soft and flexible eye and surrounding tissue compatible outer layer (2 17. The ocular insert of claim 16 wherein said inner core is comprised of a polymer selected from the group consisting of plasticized or unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, silicone rubber, polyethylene, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross linked hydrophilic polyether gel, cross linked polyvinyl alcohol, cross linked partially hydrolyzed polyvinyl acetate, cellulosic gel, ion-exchange resin and plasticized polyethylene terephthalate.

18. The ocular insert of claim 17 wherein the drug is chloramphenicol and the polymeric material of the inner core is polyethylene terephthalate.

member selected from the group consisting of pilocarpine and pilocarpine perfluorobutyrate and the polymeric material of the inner core is polyvinyl chloride.

22. The ocular insert of claim 17 wherein the drug is dexamethasone and the polymeric material of the inner core is nylon-66.

I? 1 i t i UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,630,200 Dated December 28, 197]- Inventor(s) Takeru Higuchi It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 5, lines 18 through 22 inclusive should be deleted.

Claim 1, line 73, after "flexible" add: hydrophilic outer layer insoluble in tear liquid, compatible with the eye and surrounding tissue and permeable to passage of the drug.

Claim 12, lines 31 and 32, "systematically" should read systemically Claim 16, line 55, "(1)" should read (2) Signed and sealed this 26th day of September 1972.

(SEAL) Attest:

EDWARD MGFLETCHERJR. ROBERT GOT'I'SCHALK Attasting Officer Commissioner of Patents FORM PO'WSO (059) USCOMM DC 60376 P69 v I a [1.5. GOVERNMENT PRINYING OFFICE: 1969 365'334

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3006338 *Oct 7, 1954Oct 31, 1961Johnson & JohnsonNon-adherent surgical dressing
US3220960 *Dec 21, 1960Nov 30, 1965Wichterle OttoCross-linked hydrophilic polymers and articles made therefrom
US3301257 *Jul 15, 1963Jan 31, 1967Johnson & JohnsonAbsorbent surgical dressing
US3416530 *Mar 2, 1966Dec 17, 1968Richard A. NessEyeball medication dispensing tablet
US3490454 *Oct 21, 1966Jan 20, 1970United Merchants & MfgCatamenial products having a coating of rupturable microcapsules containing medicants
US3520949 *Jul 26, 1966Jul 21, 1970Nat Patent Dev CorpHydrophilic polymers,articles and methods of making same
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3677233 *Mar 19, 1971Jul 18, 1972White Pierce H JrLivestock insecticide applicator
US3797485 *Mar 26, 1971Mar 19, 1974Alza CorpNovel drug delivery device for administering drug into blood circulation in blood vessel
US3811444 *Dec 27, 1972May 21, 1974Alza CorpBioerodible ocular device
US3826258 *Feb 7, 1972Jul 30, 1974Abraham SGradual release medicine carrier
US3828777 *Nov 8, 1971Aug 13, 1974Alza CorpMicroporous ocular device
US3845770 *Jun 5, 1972Nov 5, 1974Alza CorpOsmatic dispensing device for releasing beneficial agent
US3854480 *Jun 2, 1970Dec 17, 1974Alza CorpDrug-delivery system
US3868445 *Nov 16, 1973Feb 25, 1975Pharmacia AbDosage unit containing a substance showing a topical effect on the eye, and a method of preparing same
US3901232 *Oct 26, 1973Aug 26, 1975Alza CorpIntegrated device for administering beneficial drug at programmed rate
US3901969 *Sep 10, 1973Aug 26, 1975Union CorpSustained release of methantheline
US3914402 *Jun 14, 1973Oct 21, 1975Alza CorpOphthalmic dosage form, for releasing medication over time
US3960150 *Sep 15, 1975Jun 1, 1976Alza CorporationBioerodible ocular device
US3961628 *Apr 21, 1975Jun 8, 1976Alza CorporationOcular drug dispensing system
US3963025 *Jun 2, 1975Jun 15, 1976Alza CorporationOcular drug delivery device
US3976071 *Jan 7, 1974Aug 24, 1976Dynatech CorporationMethods of improving control of release rates and products useful in same
US3981303 *Jul 31, 1975Sep 21, 1976Alza CorporationBioerodible ocular device
US3986510 *Aug 1, 1975Oct 19, 1976Alza CorporationBioerodible ocular device
US3993071 *Jul 24, 1975Nov 23, 1976Alza CorporationBioerodible ocular device
US3993073 *Mar 3, 1975Nov 23, 1976Alza CorporationNovel drug delivery device
US4008719 *Feb 2, 1976Feb 22, 1977Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4014334 *Feb 2, 1976Mar 29, 1977Alza CorporationLaminated osmotic system for dispensing beneficial agent
US4135514 *Mar 9, 1977Jan 23, 1979Alza CorporationOsmotic releasing system for administering ophthalmic drug to eye of animal
US4142526 *Mar 9, 1977Mar 6, 1979Alza CorporationOsmotic releasing system with means for changing release therefrom
US4290426 *Dec 31, 1979Sep 22, 1981Alza CorporationDispenser for dispensing beneficial agent
US4454148 *Dec 9, 1982Jun 12, 1984Merck & Co., Inc.5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4659584 *Apr 11, 1986Apr 21, 1987Dr. Karl Thomae GmbhEye rod, process and apparatus for loading the same with solutions or suspensions of active substance
US4667032 *Oct 10, 1985May 19, 1987Merck Frosst Canada, Inc.Leukotriene biosynthesis inhibitors, antiallergens, antiinflammatory agents
US4859667 *Jan 14, 1987Aug 22, 1989Merck Frosst Canada, Inc.Pharmaceutical compositions of phenothiazone derivatives and analogs
US5104899 *Aug 13, 1990Apr 14, 1992Sepracor, Inc.Methods and compositions for treating depression using optically pure fluoxetine
US5135592 *Dec 27, 1989Aug 4, 1992Minnesota Mining And Manufacturing CompanyHigh quality bonding
US5152788 *Dec 27, 1989Oct 6, 1992Minnesota Mining And Manufacturing CompanyMultifocal diffractive ophthalmic lens and method of manufacture
US5225196 *Jan 7, 1991Jul 6, 1993Columbia Laboratories, Inc.Bioadhesive compositions and methods of treatment therewith
US5314419 *Oct 30, 1992May 24, 1994Pelling George EMethod for dispensing ophthalmic drugs to the eye
US5378475 *Feb 21, 1991Jan 3, 1995University Of Kentucky Research FoundationSustained release drug delivery devices
US5410054 *Jul 20, 1993Apr 25, 1995Merck Frosst Canada, Inc.Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5472436 *Jul 26, 1994Dec 5, 1995Fremstad; Daria A.Device for delivering a liquid to an eye
US5589511 *Apr 15, 1994Dec 31, 1996Sepracor Inc.Method for treating migraine headaches using optically pure S(+) fluoxetine
US5618274 *Apr 8, 1994Apr 8, 1997Rosenthal; Kenneth J.Method and device for deep pressurized topical, fornix applied "nerve block" anesthesia
US5648396 *Jun 7, 1995Jul 15, 1997Sepracor Inc.Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5660851 *Jun 5, 1995Aug 26, 1997Yissum Research Development Company Of The Hebrew Univ. Of JerusalemCovalent attachmentof a carboxylic acid-containing active material through anhydride bonds to a polymer that contains pendant carboxylic acid groups; drug delivery
US5708035 *May 22, 1995Jan 13, 1998Sepracor Inc.Methods of use and compositions of R(-) fluoxetine
US5766619 *May 4, 1993Jun 16, 1998Aiache; Jean-MarcPharmaceutical dosage form for ocular administration and preparation process
US5902598 *Aug 28, 1997May 11, 1999Control Delivery Systems, Inc.Sustained release drug delivery devices
US6110973 *Jan 28, 1999Aug 29, 2000SepracorMethods for treating obesity and weight gain using optically pure (-)-bupropion
US6196993Apr 19, 1999Mar 6, 2001Eyelab Group, LlcOphthalmic insert and method for sustained release of medication to the eye
US6197788Nov 26, 1998Mar 6, 2001Vernalis Research Limited(−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6200257 *Mar 24, 1999Mar 13, 2001Proxima Therapeutics, Inc.Catheter with permeable hydrogel membrane
US6277887Apr 20, 2000Aug 21, 2001Sepracor, Inc.Methods for treating Parkinson's disease using optically pure (−)-bupropion
US6337328Aug 18, 2000Jan 8, 2002Sepracor, Inc.Bupropion metabolites and methods of use
US6342496Feb 22, 2000Jan 29, 2002Sepracor Inc.Bupropion metabolites and methods of use
US6369113Jun 27, 2001Apr 9, 2002Sepracor, Inc.Antidepressants, parkinson's disease
US6375972Apr 26, 2000Apr 23, 2002Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6451860Feb 19, 2002Sep 17, 2002Sepracor, Inc.Methods for treating depression and other disorders using optically pure (−)-bupropion
US6458374Jan 28, 1999Oct 1, 2002Sepracor, Inc.Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US6495605Mar 13, 2001Dec 17, 2002Sepracor Inc.Pure isomers
US6537194Nov 28, 2000Mar 25, 2003Proxima Therapeutics, Inc.Catheter with permeable hydrogel membrane
US6559188Sep 15, 2000May 6, 2003Novartis AgMethod of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6664397Mar 6, 1998Dec 16, 2003Vernalis Research LimitedAdministering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects
US6734213May 17, 2002May 11, 2004Smithkline Beecham CorporationAdministering (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or salts and solvates thereof to treat alcoholism
US6855820May 17, 2002Feb 15, 2005Smithkline Beecham CorporationTreating racemic 2-(chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol with p-toluyl-L-tartaric acid(a chiral acid) in a suitable solvent to form a mixture of diastereomeric salts; isolating the salt, reacting with base
US6878749Jan 16, 2003Apr 12, 2005Novartis AgMethod of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6951873Mar 3, 2000Oct 4, 2005Pfizer Inc.Cognitive dysfunction syndrome in cats and dogs; substituted piperidines, fused heterocycles
US6998400May 17, 2002Feb 14, 2006Smithkline Beecham CorporationPharmaceutically active morpholinol
US7034059Jun 28, 2002Apr 25, 2006Sepracor Inc.Reducing production of PGE2; treating autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, and cancer
US7098206May 17, 2002Aug 29, 2006Smithkline Beecham CorporationPsychological disorders; antidepressants;
US7105333Mar 27, 2002Sep 12, 2006Deadreon CorporationNucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430May 14, 2002Sep 26, 2006Dendreon CorporationNucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7125703Mar 13, 2002Oct 24, 2006Dendreon CorporationNucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892Mar 20, 2002Feb 6, 2007Dendreon CorporationExhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
US7229640Dec 18, 2001Jun 12, 2007Smithkline Beecham P.L.C.Paroxetine controlled release compositions
US7276364Nov 20, 2000Oct 2, 2007Dendreon CorporationNucleic acids encoding endotheliases, endotheliases and uses thereof
US7585517 *Sep 20, 2004Sep 8, 2009Macusight, Inc.delivery system contains a solid core of rapamycin or other therapeutic agent
US7700341Feb 2, 2001Apr 20, 2010Dendreon CorporationNucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7767429Mar 5, 2004Aug 3, 2010Halozyme, Inc.use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms; HYLENEX RECOMBINANT tradename
US7829081Mar 4, 2010Nov 9, 2010Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7846431Mar 4, 2010Dec 7, 2010Halozyme, Inc.Composition comprising hyaluronidase glycoprotein that is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine for use in treatment of diabetic disorders
US7871607Feb 23, 2005Jan 18, 2011Halozyme, Inc.use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant soluble neutral active Hyaluronidase Glycoproteins to enhance stability and serum pharmacokinetics over natural slaughterhouse enzymes; transgenic animals; dosage forms
US7888092Oct 30, 2009Feb 15, 2011Dendreon CorporationNucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7928132Aug 6, 2004Apr 19, 2011Ohio UniversityMethods for the amelioration of episodes of acute or chronic ulcerative colitis
US8105586Jun 15, 2010Jan 31, 2012Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8202517Feb 20, 2009Jun 19, 2012Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8211428Jul 5, 2007Jul 3, 2012Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified thereby
US8222271Mar 23, 2007Jul 17, 2012Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8252307Jan 8, 2010Aug 28, 2012Psivida Us, Inc.Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US8257699Dec 15, 2011Sep 4, 2012Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8367097May 12, 2010Feb 5, 2013Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8394807Nov 20, 2009Mar 12, 2013Purdue Research FoundationQuinazoline inhibitors of BACE 1 and methods of using
US8431124Apr 16, 2009Apr 30, 2013Halozyme, Inc.Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US8431380Feb 20, 2009Apr 30, 2013Halozyme, Inc.facilitate drug delivery of other molecules; e.g. use intraocularly in eye surgery, glaucoma, retinopathy treatments
US8450470Jun 3, 2009May 28, 2013Halozyme, Inc.Use to faciliate drug delivery of other drugs, or treat glycosaminoglycan associated pathologies, such as scarring, spinal cord injury, glaucoma, and cosmetic treatments
US8486960Jun 21, 2012Jul 16, 2013Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8492400Feb 9, 2007Jul 23, 2013Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8574613Jan 19, 2010Nov 5, 2013Psivida Us, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8574659Jan 15, 2010Nov 5, 2013Psivida Us, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8580252Jul 6, 2012Nov 12, 2013Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8637070Feb 9, 2006Jan 28, 2014Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US8658667Jun 24, 2013Feb 25, 2014Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8663633Jul 2, 2012Mar 4, 2014Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified thereby
US8663639Aug 18, 2008Mar 4, 2014Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
US8703947Oct 9, 2009Apr 22, 2014Purdue Research FoundationCompounds for treatment of Alzheimer's disease
US8765166Jul 22, 2013Jul 1, 2014Novaer Holdings, Inc.Drug delivery devices for delivery of ocular therapeutic agents
US8765685May 16, 2012Jul 1, 2014Halozyme, Inc.Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)
US8772246Oct 18, 2012Jul 8, 2014Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8815558May 29, 2009Aug 26, 2014Halozyme, Inc.Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
EP0206741A2Jun 17, 1986Dec 30, 1986Merck Frosst Canada Inc.Leukotriene antagonists
EP0239306A2Mar 18, 1987Sep 30, 1987Merck Frosst Canada Inc.Tetrahydrocarbazole esters
EP0435525A2 *Dec 14, 1990Jul 3, 1991Nestle S.A.Multifocal diffractive ophthalmic lens and method of manufacture
EP0480716A1Oct 10, 1991Apr 15, 1992Merck Frosst Canada Inc.Saturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0577646A1 *Feb 21, 1992Jan 12, 1994University Of Kentucky Research FoundationSustained release drug delivery devices
EP0861659A1 *Feb 21, 1992Sep 2, 1998University Of Kentucky Research FoundationSustained release drug delivery devices
EP2011507A2Sep 15, 2000Jan 7, 2009Novartis AGPharmaceutical composition of nateglinide and another antidiabetic agent
EP2163643A1Mar 5, 2004Mar 17, 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2177620A1Mar 5, 2004Apr 21, 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2218779A1Dec 15, 2003Aug 18, 2010Halozyme, Inc.Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2233112A2 *Oct 26, 2004Sep 29, 2010PSivida US Inc.Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
EP2298874A1Dec 15, 2003Mar 23, 2011Halozyme, Inc.Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2311973A1Mar 5, 2004Apr 20, 2011Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2330213A1Mar 5, 2004Jun 8, 2011Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2399578A1May 11, 2006Dec 28, 2011The Interthyr CorporationMethods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
EP2402437A2Jul 5, 2007Jan 4, 2012Catalyst Biosciences, Inc.Protease screening methods and proteases identified thereby
EP2402438A2Jul 5, 2007Jan 4, 2012Catalyst Biosciences, Inc.Protease screening methods and proteases identified thereby
EP2405015A2Mar 5, 2004Jan 11, 2012Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2662090A1Apr 14, 2009Nov 13, 2013Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2772225A1 *Mar 14, 2002Sep 3, 2014THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESOcular therapeutic agent delivery devices and methods for making and using such devices
WO1984004680A1 *May 25, 1983Dec 6, 1984Alcon Lab IncOphthalmic gel
WO1984004681A1 *May 25, 1983Dec 6, 1984Alcon Lab IncOphthalmic solution
WO1993021901A1 *May 5, 1993Nov 11, 1993Aiache Jean MarcGalenic form for ocular administration and process for the preparation of same
WO2003077847A2Mar 7, 2003Sep 25, 2003Helen M ArmstrongSubstituted amides
WO2004081001A1Feb 13, 2004Sep 23, 2004Banyu Pharma Co LtdNovel 2-pyridinecarboxamide derivatives
WO2005051234A2 *Oct 26, 2004Jun 9, 2005Paul AshtonInjectable sustained release implant having a bioerodible matrix core and a bioerodible skin
WO2005066126A1Dec 13, 2004Jul 21, 2005Lilly Co EliCb1 modulator compounds
WO2005089767A1Mar 10, 2005Sep 29, 2005Barton Aron KamenUse of aminopterin for treating cancer and inflammatory disorders
WO2006049304A1Nov 1, 2005May 11, 2006Banyu Pharma Co LtdAryloxy-substituted benzimidazole derivatives
WO2006091871A1Feb 23, 2006Aug 31, 2006Halozyme Therapeutics IncSoluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2007037534A1Sep 29, 2006Apr 5, 2007Banyu Pharma Co Ltd2-heteroaryl-substituted indole derivative
WO2008044777A1Oct 5, 2007Apr 17, 2008Masanori Asai2-pyridinecarboxamide derivative having gk-activating activity
WO2008066131A1Nov 29, 2007Jun 5, 2008Banyu Pharma Co LtdNovel phenyl-isoxazol-3-ol derivative
WO2008094476A1Jan 25, 2008Aug 7, 2008Merck & Co IncSubstituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators
WO2009063821A1Nov 10, 2008May 22, 2009Banyu Pharma Co LtdHeteroaryloxy quinazoline derivative
WO2009081782A1Dec 15, 2008Jul 2, 2009Banyu Pharma Co LtdN-pyrazole-2-pyridinecarboxamide derivative
WO2009147990A1May 28, 2009Dec 10, 2009Banyu Pharmaceutical Co.,Ltd.Novel isoxazole derivative
WO2010077297A1Dec 9, 2009Jul 8, 2010Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
WO2010095767A1Feb 22, 2010Aug 26, 2010Banyu Pharmaceutical Co.,Ltd.Pyrimidin-4(3h)-one derivatives
WO2010102262A1Mar 5, 2010Sep 10, 2010Halozyme, Inc.Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
WO2010104195A1Mar 9, 2010Sep 16, 2010Banyu Pharmaceutical Co.,Ltd.Novel isoindolin-1-one derivative
WO2010127452A1May 4, 2010Nov 11, 2010The Royal Institution For The Advancement Of Learning/Mcgill University5-oxo-ete receptor antagonist compounds
WO2011106273A1Feb 21, 2011Sep 1, 2011Merck Sharp & Dohme Corp.Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2013040501A1Sep 14, 2012Mar 21, 2013Pharmathene, Inc.Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
WO2013101926A1Dec 27, 2012Jul 4, 2013Allergan, Inc.Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013142380A1Mar 15, 2013Sep 26, 2013The Regents Of The University Of CaliforniaOncovector nucleic acid molecules and methods of use
WO2014093189A1Dec 9, 2013Jun 19, 2014Merck Sharp & Dohme Corp.Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
WO2014096854A2Dec 20, 2013Jun 26, 2014Coopervision International Holding Company, LpOphthalmic devices for delivery of beneficial agents
WO2014107745A1Jan 7, 2014Jul 10, 2014Halozyme, Inc.Metal sensitive mutants of matrix metalloproteases and uses thereof
Classifications
U.S. Classification424/427
International ClassificationA61F9/00, A61K9/00
Cooperative ClassificationA61F9/0017, A61K9/0051
European ClassificationA61K9/00M16B, A61F9/00B2